MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5152/eurjrheum.2024.24013

Медицинская библиотека · European journal of rheumatology · 2024

Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study.

Durak Ediboğlu Elif, Çınar Muhammed, Kozacı Didem, Solmaz Dilek, Sargın Gökhan, Karadağ Ömer, Kınıklı Gülay, Kalyoncu Umut, Yılmaz Sedat, Şentürk Taşkın, Kabadayı Gökhan, Keser Gökhan, Hatemi Gülen, Kaya Kübra, Özmen Mustafa, Yargucu Figen, Özgüler Yeşim, Cefle Ayşe, Gerçik Önay, Kısacık Bünyamin, Akar Servet

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA).

METHODS

Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE).

RESULTS

A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb.

CONCLUSION

The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up.

Для цитирования: Durak Ediboğlu Elif, Çınar Muhammed, Kozacı Didem, Solmaz Dilek, Sargın Gökhan, Karadağ Ömer, Kınıklı Gülay, Kalyoncu Umut, Yılmaz Sedat, Şentürk Taşkın, Kabadayı Gökhan, Keser Gökhan, Hatemi Gülen, Kaya Kübra, Özmen Mustafa, Yargucu Figen, Özgüler Yeşim, Cefle Ayşe, Gerçik Önay, Kısacık Bünyamin, Akar Servet. Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study.. European journal of rheumatology. 2024. DOI: 10.5152/eurjrheum.2024.24013.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.